Obagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin’s Age and Restore Visible Youthfulness
Obagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™
Waldencast (WALD) had its price target lowered by Telsey Advisory Group from $3.00 to $2.00. They now have a "market perform" rating on the stock.
Waldencast (WALD) had its price target lowered by Canaccord Genuity Group Inc. from $4.00 to $2.00. They now have a "buy" rating on the stock.
Waldencast Reports Q4 2025 and FY 2025 Financial Results [Yahoo! Finance]